Project Grant R01CA281885
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$656K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Duke University to conduct a randomized controlled trial (RCT) evaluating the efficacy of a telehealth-delivered psychosocial intervention called ENGAGE. The $578,467 award, effective from August 1, 2024 to July 31, 2029, aims to test the ability of ENGAGE to reduce symptom interference (primary outcome) and improve secondary outcomes like self-efficacy, acceptance,...
The National Cancer Institute (NCI) has awarded a $621,732 project grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC). The grant will fund a 5-year hybrid effectiveness-implementation trial to evaluate a proactive identification and digital mental health intervention approach to address unmet psychosocial needs of individuals living with likely incurable cancer. The key products and services to be delivered through this...
The National Cancer Institute (NCI) awarded a $173,997 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Duke University. The funding will support a pilot randomized controlled trial to assess the feasibility, acceptability, and outcome patterns of the NITE2DAY+ intervention, which aims to improve insomnia, fatigue, distress, and pain symptoms in hematologic cancer patients during and after inpatient treatment. The NITE2DAY+ intervention incorporates...
This Project Grant award in the amount of $1,500,000 was provided by the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393). The funding will support a study by the University of Rochester to examine how the structural characteristics, functional aspects, and quality of social networks of older adults with advanced cancer influence end-of-life health behaviors, such as participating in serious illness conversations, completing advance...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $709,050.00 to the University of North Carolina at Chapel Hill to conduct a randomized controlled trial of the "FORTITUDE" eHealth intervention. The goal is to evaluate the efficacy of this targeted intervention in reducing fear of recurrence among breast cancer survivors in community oncology settings, as well as its impact on psychological, behavioral,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $979,000.00 to the Beckman Research Institute of the City of Hope to develop and test a blended e-health intervention to address fear of progression (FOP) in patients with advanced gynecologic cancer. The proposed intervention combines group videoconferencing sessions, web-based self-study modules, and facilitator check-in calls to provide tailored support using acceptance and commitment...
The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, supports the development and evaluation of the Integrated Cancer Awareness Network (ICAN), an innovative mobile health (mHealth) platform. The ICAN platform aims to educate primary care...
This $594,734 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and evaluation of a telehealth exercise program for rural cancer survivors experiencing cancer-related fatigue (CRF). The project, titled "Effects of a Telehealth Exercise Program for Rural Cancer Survivors with Cancer-Related Fatigue Including Integrated Longitudinal Assessments of Objective Physical Function and Fatty Acid Oxidation", will be...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a 5-year, $599,339 randomized trial to evaluate the efficacy of a multidisciplinary group-based telehealth intervention called HORIZONS. The intervention aims to improve quality of life, psychological distress, symptom burden, coping, and self-efficacy in hematopoietic stem cell transplant (HCT) survivors living with chronic graft-versus-host disease...
The National Cancer Institute (NCI) awarded a $696,140 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York, Health Sciences Division, to develop and test the ICAN DEPCARE strategy. This hybrid III effectiveness-implementation trial aims to efficiently and sustainably deliver complex treatment algorithms/guidelines, facilitate communication/triage/referral processes for oncology teams, and increase the proportion of...